HIV-associated nephropathy: Role of mammalian target of rapamycin pathway

American Journal of Pathology

Volumn 177, Issue 2, 2010, Pages 813-821

  Kumar, Dileep ^a   Konkimalla, Sridevi ^a   Yadav, Anju ^a   Sataranatarajan, Kavithalakshmi ^b   Kasinath, Balakuntalam S ^b   Chander, Praveen N ^c   Singhal, Pravin C ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SODIUM CHLORIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; TRANSGENIC MOUSE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 77957267854     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100131     Document Type: Article

References (42)

1. Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, Scheel PJ, Atta MG: Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008, 28:478-486
2. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD: The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009, 75:428-434
3. Gulati P, Thomas G: Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem Soc Trans 2007, 35:236-238
4. Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL: TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995, 82:121-130
5. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168
6. Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, Lawrence JC Jr: cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci USA 1995, 92:7222-7226
7. Kasinath BS, Feliers D, Sataranatarajan K, Ghosh Choudhury G, Lee MJ, Mariappan MM: Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 2009, 297:F1153-F1165
8. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 2006, 17:3281-3292
9. Dzau VJ, Braun-Dullaeus RC, Sedding DG: Vascular proliferation and atherosclerosis: new perspective and therapeutic strategies. Nat Med 2002, 8:1249-1256
10. Savikko J, von Willebrand E: Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model. Transplant Proc 2006, 38:2699-2700
11. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006, 103:5466-5471
12. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007, 27:495-502 (Pubitemid 47482007)
13. Esposito C, Villa L, Grosjean F, Mangione F, Esposito V, Castoldi F, Serpieri N, Arra M, Pertile E, Maggi N, Valentino R, Dal Canton A: Rapamycin reduces proteinuria and renal damage in the rat remnant kidney model. Transplant Proc 2009, 41:1370-1371
14. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, Klotman PE: Progressive glomerulo-sclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 1992, 89:1577-1581
15. Arora S, Husain M, Kumar D, Patni H, Pathak S, Mehrotra D, Reddy VK, Reddy LR, Salhan D, Yadav A, Mathieson PW, Saleem MA, Chander PN, Singhal PC: Human immunodeficiency virus downregulates podocyte apoE expression. Am J Physiol Renal Physiol 2009, 297:F653-F61
16. Holz MK, Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005, 280:26089-26093
17. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 2007, 171:1733-1742
18. Korgaonkar SN, Feng X, Ross MD, Lu TC, D'Agati V, Iyengar R, Klotman PE, He JC: HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008, 19:877-883
19. Land SC, Tee AR: Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007, 282:20534-20543
20. Slomiany MG, Rosenzweig SA: Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 2006, 318:666-675
21. Gharavi AG, Ahmad T, Wong RD, Hooshyar R, Vaughn J, Oller S, Frankel RZ, Bruggeman LA, D'Agati VD, Klotman PE, Lifton RP: Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci USA 2004, 101:2488-2493
22. Chan KT, Papeta N, Martino J, Zheng Z, Frankel RZ, Klotman PE, D'Agati VD, Lifton RP, Gharavi AG: Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus. Kidney Int 2009, 75:366-372
23. Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, Ballard D, Bruggeman LA, Frankel R, Zheng Z, Klotman PE, Zhao H, D'Agati VD, Lifton RP, Gharavi AG: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 2009, 119:1178-1188
24. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA, Andreau K, Perfettini JL, Amendola A, Nardacci R, Leduc P, Ingber DE, Druillennec S, Roques B, Leibovitch SA, Vilella-Bach M, Chen J, Este JA, Modjtahedi N, Piacentini M, Kroemer G: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002, 21:4070-4080
25. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184
26. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005, 16:46-51
27. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL: Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 2009, 297:F1597-F1605
28. Lieberthal W, Levine JS: The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009, 20:2493-2502
29. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL, Yoshimura A: The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 2009, 384:471-475
30. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulo-interstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005, 16:2063-2072
31. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C: The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 2008, 108:e45-e56
32. Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005, 16:1384-1391
33. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC: S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2009, 297:F585-F593
34. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006, 69:2029-2036
35. Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004, 65:2003-2017
36. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S: Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 2006, 69:1986-1995
37. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716
38. Müller-Deile J, Worthmann K, Saleem MA, Tossidou I, Haller H, Schiffer M: The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009, 297:F1656-F1667
39. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E, Bruijn JA: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007, 71:637-645
40. Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M: Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Transplant Proc 2009, 41:2789-2793
41. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C: The mTOR Inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007, 84:1492-1496
42. Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M: Sirolimus delays recovery from post-transplant renal failure in kidney graft recipients. Transplant Proc 2005, 37:839-842